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Abstract
Amyotrophic lateral sclerosis (ALS) is a lethal motor neuron disease that progressively debilitates neuronal cells that control
voluntary muscle activity. Biomarkers are urgently needed to facilitate ALS diagnosis and prognosis, and as indicators of
therapeutic response in clinical trials. microRNAs (miRNAs), small posttranscriptional modifiers of gene expression, are
frequently altered in disease conditions. Besides their important regulatory role in variety of biological processes, miRNAs
can also be released into the circulation by pathologically affected tissues and display remarkable stability in body fluids. In
a mouse model of ALS that expresses mutated human superoxide dismutase 1 (SOD1-G93A) skeletal muscle is one of the
tissues affected early by mutant SOD1 toxicity. To find biomarkers for ALS, we studied miRNA alterations from skeletal
muscle and plasma of SOD1-G93A mice, and subsequently tested the levels of the affected miRNAs in the serum from
human ALS patients. Fast-twitch and slow-twitch muscles from symptomatic SOD1-G93A mice (age 90 days) and their
control littermates were first studied using miRNA microarrays and then evaluated with quantitative PCR from five age
groups from neonatal to the terminal disease stage (10–120 days). Among those miRNA changed in various age/gender/
muscle groups (miR-206, -1, -133a, -133b, -145, -21, -24), miR-206 was the only one consistently altered during the course of
the disease pathology. In both sexes, mature miR-206 was increased in fast-twitch muscles preferably affected in the SOD1-
G93A model, with highest expression towards the most severely affected animals. Importantly, miR-206 was also increased
in the circulation of symptomatic animals and in a group of 12 definite ALS patients tested. We conclude that miR-206 is
elevated in the circulation of symptomatic SOD1-G93A mice and possibly in human ALS patients. Although larger scale
studies on ALS patients are warranted, miR-206 is a promising candidate biomarker for this motor neuron disease.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease
that affects 4–6 individuals per 100 000 worldwide, a lifetime risk
for developing the condition being approximately one in 400 [1,2].
ALS leads to degeneration of upper and lower motor neurons. The
clinical disease is characterized by progressive skeletal muscle
weakness/atrophy and in majority of patients culminates in fatal
respiratory paralysis within 3–5 years of the onset of symptoms.
There is no cure for ALS and the only approved disease-modifying
drug, Riluzole, slows the progression to death only modestly [3].
The identification of ALS is complicated and time consuming as
no test can currently establish the disease. The diagnostic process
relies on series of clinical examinations combined with electro-
diagnostics and other tests to rule out alternative disorders with a
similar presentation. Indeed, a significant overlap with some
clinically alike conditions at the early stage of ALS considerably
delays the progress to the definite diagnosis [4,5]. While the
etiology of ALS at large remains unknown, both environmental
and genetic factors are known to be involved. Most cases are
sporadic (SALS) and approximately 5% have family history
(FALS) [6]. However, the two forms of the disease are clinically
indistinguishable. Causes of FALS have been mapped to more
than 20 genes [7] and mutations in superoxide dismutase 1
(SOD1), account for approximately one fifth of FALS and a small
percentage of apparently sporadic cases.
A transgenic mouse strain overexpressing one of the pathogenic
human SOD1 alleles, SOD1-G93A, is a frequently used transgenic
model of ALS [8,9]. Most ALS-linked SOD1 mutations are
thought to exert their molecular effects through toxic gain of
function(s) by the mutant enzyme [10]. Although the exact nature
of the novel molecular properties gained remains elusive, mutant
SOD1 (mSOD1) models mimic the main features of ALS and
have offered valuable insights to the basic pathology of the disease.
One of these is that ALS is not simply a neuronal disease. Neuron-
restricted expression of the mSOD1 is not always sufficient to
cause the disease [11,12], although this may depend on neuronal
mSOD1 load [13]. Contribution by non-neural cells such as
neuroglia, however, is evident [14] and altered function of
inhibitory interneurons that monitor and control motor neuron
activity may be involved [15]. Furthermore, skeletal muscle-
autonomous mSOD1 toxicity strongly contributes to the disease
progression in these models; muscle-restricted expression of the
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mSOD1 is sufficient to trigger ALS symptoms and muscle atrophy
[16] as well as motor neuron degeneration [17]. Muscle atrophy in
rodent models and ALS patients is also associated with similar
perturbations in molecular networks controlling muscle organiza-
tion and function including autophagy, mitochondrial homeosta-
sis, hypermetabolism and myosatellite cell function [16,18–24].
Therefore, structural and metabolic alterations in cells that
connect with neurons, including skeletal muscle, may synergisti-
cally exacerbate the disease outcome.
At early stages of ALS pathology, motor neuron cell bodies in
the central nervous system remain mostly intact. Motor neuron
degeneration initiates by distal withdrawal of nerve terminals from
the neuromuscular junction (NMJ) and proceeds retrogradely
along the motor axon. This ‘‘dying back’’ pathology is observed in
both SOD1-G93A mice and post-mortem samples from human
ALS patients [25,26]. Motor units, functional units of the motor
system, consist of a single motor neuron and a group or muscle
fibers with similar properties. The denervation in ALS preferen-
tially affects large, fast-conducting motor neurons and, as a result,
fast-twitch motor units are more vulnerable to the pathology than
slow-twitch units [26–29]. The symptomatic stage characterized
by tremors and hind-leg spasticity commences in SOD1-G93A
mice approximately at postnatal day 90 [8]. However, muscle
girth measurements, medical imaging and histological findings all
indicate loss of hind-limb muscle volume and decreased fast
muscle fiber diameter before the age of 60 days [30,31]. This
suggests early subclinical pathology of skeletal muscle in mSOD1
models.
microRNAs (miRNAs) are evolutionarily conserved non-coding
RNA molecules involved in post-transcriptional regulation of gene
expression. This regulation is achieved by pairing of miRNA with
complementary sequences found in its target mRNAs [32]. The
usual consequence of the miRNA:mRNA binding is a downreg-
ulation of the corresponding mRNA and/or protein levels due to
mRNA destabilization or translational inhibition. Recent evidence
gained through simultaneous mRNA and proteomic/ribosomal
profiling suggests that the former is dominant in mammalian cells
[33–35]. miRNAs are frequently altered in conditions such as
cancer, cardiovascular and metabolic diseases, and in disorders of
central nervous system [36–39]. miRNAs are known to be secreted
by various cell types and, unlike most mRNAs, are remarkably
stable in circulating body fluids due to proteic or vesicular
protection from ribonucleases [40–42]. Because of these properties
miRNAs have recently gained attention for their potential as
minimally invasive and cost-effective disease biomarkers.
Here, we first studied by microarrays how miRNA expression is
affected in vulnerable (fast) and resistant (slow) muscle types of
symptomatic SOD1-G93A mice. The rationale for using skeletal
muscle was based on its contribution to the ALS pathology in mice
[16,17] and on the fact that it represents the largest tissue in the
human body, possessing a great potential to release miRNAs to the
circulation. The selected candidate miRNAs from the microarray
data were then investigated individually with quantitative PCR
(qPCR) from neonatal, presymptomatic, symptomatic and termi-
nal stage mice in the two muscle types and in the circulation of
same model. The relative abundance of the implicated miRNAs
was finally measured in serum samples from ALS patients and
control individuals. The data indicates that muscle-enriched miR-
206 may serve as a non-invasive circulating biomarker for ALS,
and warrants larger scale studies on SALS and FALS patients.
Results
Muscle miRNA Profile in Symptomatic SOD1-G93A Mice
To gain first insight into the miRNA expression in the skeletal
muscle tissue of SOD1-G93A animals, RNA derived from fast
extensor digitorum longus (EDL) and slow soleus (SOL) muscles of
mutant (denoted +) and control (denoted -) mice at postnatal day
P90 (P+days of age) was analysed with miRNA microarrays. It was
first assessed how miRNA profile is altered in each muscle type of
the mutant compared to the wild type littermates (EDL+ vs.
EDL2, and SOL+ vs. SOL2). Secondly, we analysed which
miRNA species are significantly more expressed in one of the
muscle types in the normal context (EDL2 vs. SOL2) and if this
enrichment is affected in the mutants (EDL+ vs. SOL+). For main
subtypes of probesets found in the arrays were mature miRNA
(miRNA), passenger RNA (miRNA*) and stem-loop (pre-miRNA).
Some probesets corresponding to non-miRNA species (fragments
of tRNA, rRNA, mtDNA etc.) are listed on the Tables S1, S3 and
S4 but were not considered as real miRNA changes.
Without multiple corrections (see Materials and methods),
comparison of SOD1-G93A with controls revealed 179 significant
(p,0.05) changes in EDL+ (108 up, 71 down), and 42 changes in
SOL+ (19 up, 23 down). Only 12 probesets were common among
those affected in EDL+ and SOL+ muscles, leaving 167 mutant
EDL-specific changes and 30 changes specific to mutant SOL
muscle (Figure 1, see also clustering of the affected probesets in
Figure S1). The fold changes associated with SOD1-G93A
expression in the EDL varied from 11.9 fold upregulation to
24.2 fold downregulation and in SOL from 2.7 fold upregulation
to 22.6 fold downregulation. The most upregulated mature
miRNA in the mutant EDL were on average more highly
expressed (7.860.6 fold) than most upregulated miRNA* (3.660.6
fold, p,0.001) or pre-miRNA (1.960.3 fold, p,0.001) species,
whereas most downregulated mature miRNA did not significantly
differ from that of miRNA* or pre-miRNA (Figure S2). In EDL,
56 probesets were upregulated and 10 probesets downregulated
more than two fold, most (79%) of those being mature miRNAs
(Figure S3). In SOL, only one probeset was up and one down
more than two fold (both mature miRNAs). The complete lists of
significant changes in SOD1-G93A EDL and SOL compared to
the respective wild type muscles are shown in Tables S1 and S2,
respectively.
Comparison of the fast and slow muscle type within wild type
animals (EDL2 vs. SOL2) revealed total 118 probesets with
preferential expression in one of the muscle types (Table S3). Of
these, approximately one half were preferentially expressed in
EDL and the other half in SOL. Of those 31 probesets that were
enriched more than 2 fold in one of the muscles, 12 was primarily
expressed in EDL and 19 in SOL. Similar comparison with the
two muscle types in SOD1-G93A mutants (EDL+ vs. SOL+,
Table S4) revealed total 77 significant changes, 43 of which were
preferentially EDL expressed and 34 preferentially SOL ex-
pressed. Eight probesets were enriched more than 2 fold in one of
the muscle types (4 in EDL and 2 in SOL) in the mutants.
One quarter (25%) of the total probesets up-regulated in the
mutant EDL muscle (EDL+ vs. EDL2) were coincident with those
preferentially expressed in wild type SOL (EDL2 vs. SOL2),
most (84%) of these being SOL enriched for more than 2 fold.
Respectively, one third (32%) of the total downregulated miRNA
in the mutant EDL muscle (EDL+ vs. EDL2), were preferably
expressed in EDL of the controls (EDL2 vs. SOL2). As expected,
multiple corrections by false discovery rate (FDR), which indicates
the fraction of false positives within a list of genes exceeding a
given statistical cutoff (see materials and methods fo details)
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markedly reduced the number of significant changes in the
miRNA list. In fact only two miRNA from the EDL+ vs. EDL2
comparison remained significant (q-value,0.05) after FDR
correction, and none from SOL+ vs. SOL2 comparison. The
most promising miRNA candidates were then shortlisted for
individual assays considering following criteria: 1) published
evidence supporting that the target is real miRNA, 2) preference
for mature miRNAs, 3) preference for miRNA affected in EDL, 4)
preference for high/moderate array signal intensities to low ones,
5) preference for higher fold change and most significant p-values
and, 6) those miRNA implicated in muscle biology. Total 24
miRNA were tested first for sufficient expression level in EDL,
SOL and plasma from wild type and mutant animals. A limit
where miRNA is considered expressed in sufficient level for
reliable analysis was set to 32 PCR cycles at least in one of the
muscles and plasma (Figure S4). Sufficiently high levels of
expression was found only in 10 miRNAs: miR-133a, miR-206,
miR-1, miR-145, miR-24, miR-19b, miR-17, miR-106b, miR-20a
and miR-21. Additionally, miR-133b that was not altered in the
arrays was selected for its known function in muscle biology. Some
of the miRNA were found to be expressed in very low amounts in
muscle and not detectable in plasma. Such included some of the
most upregulated miRNA in the array data, such as miR-379,
miR-671-5p and miR-708 (Figure S4).
Disease-stage Affects miRNA Alterations in SOD1-G93A
Skeletal Muscle and Blood Plasma
The selected 11 miRNAs were examined in various postnatal
stages that in SOD1-G93A mice correspond to neonatal (P10),
early presymptomatic (P40), late presymptomatic (P60), symptom-
atic (P90) and terminal phase (P120). Individual miRNAs were
measured from EDL and plasma of male mice from all age groups,
and from EDL and plasma of females from P60, P90 and P120. As
soleus is known to be affected later in SOD1-G93A model, SOL
was tested only at two oldest age groups for both sexes. Briefly, the
only miRNA whose expression was increased consistently at any
stage/tissue/sex was miR-206. The other significantly altered
miRNAs (miR-1, -133a, -133b, -145, -21 and miR-24) were always
found to be diminished, although modestly (#50%) and varying
between the age and muscle/plasma/sex groups. All observed
miRNA alterations in the two muscles and plasma of SOD1-G93A
animals are listed in Table 1.
In SOD1-G93A males, no changes in any of the studied
miRNA were found at P10, P40 or P60, although suggestive but
non-significant upregulation of miR-206 was observed at P60 in
EDL (Figure 2A, 1.7 fold, p = 0.10) and plasma (Figure 2B, 3.8
fold, p = 0.10). At symptomatic P90, miR-206 was 7.7 fold
upregulated in EDL (p = 0.0001), 4.5 fold upregulated in plasma
(p = 0.0004). At terminal P120, miR-206 was 11.7-fold upregu-
lated in male EDL muscle (p = 0.0001) but, perhaps surprisingly,
showed a 240% decrease in circulating plasma (p = 0.04). miR-
206 was unaffected in slow SOL muscle at P90 or P120 (Figure 2A,
bars with diagonal stripes). Albeit the relative levels of miR-206 in
male EDL increased progressively towards the end stage, the
circulating miR-206 dropped dramatically from the onset of
symptoms to the terminal stage (Figures 2A and 2B). Because it
remained possible that the peak elevation in circulating miR-206
has been missed between the age groups P90 and P120, miR-206
was further studied from male mice at the age of 100–105 days
(mean 102 days in controls and 101.9 days in mutants). Indeed,
plasma miR-206 was upregulated 23.5 fold (p,0.00001,
Figure 2C) at this age.
In SOD1-G93A females (Figure 3), like in males, miRNA levels
were unchanged at P60 EDL (Figure 3A) and plasma (Figure 3B).
At P90, miR-206 was 7.1 fold increased in EDL (p = 0.0001,
Figure 3A) and its upregulation was suggestive but non-significant
in P90 plasma (3.3 fold, p = 0.09, Figure 3B). At P120, miR-206
was 4.2 fold up in female EDL (p = 0.03) to the same extent in
circulating plasma (p = 0.02). Like in males, miR-206 was
unaffected in SOL (Figure 3A, bars with diagonal stripes).
Circulating miRNAs in ALS Patients
As one of the main objectives of the study was to find out
candidate miRNA biomarkers for ALS, a small group of patient
serum samples was analysed for above mentioned 11 miRNAs.
Serum from six male and six female patients with definite ALS (El
Escorial Criteria, [43]) and from six healthy male and six healthy
female controls were studied. Average age of the patients was
57612.2 years, and that of controls 54614.5 years. Genders
separated the average age of males was 57617.9 years for patients
and 50615.7 years for controls, and for females 58610.0 and
5869.1 years, respectively. Both genders combined, the qPCR
analysis (Figure 4) indicated 4.3 fold upregulation of miR-206
(p = 0.005) and 2 fold upregulation of miR-106b (p = 0.02) in
patient versus control serum samples. Because we reasoned that
some changes may be modified by sex, we also compared the data
within gender groups. Comparison of male patients with male
controls did not result in significant changes, although miR-206
was close to significance (3.4 fold upregulation, p = 0.1, Figure
S5A). Comparison of female patients with female controls resulted
in significant 5.4 fold upregulation of miR-206 (p = 0.02), 2-fold
upregulation of miR-133b (p = 0.03) and 1.4 fold upregulation of
miR-145 (p = 0.04) (Figure S5B).
Discussion
The study examined miRNA alterations in the skeletal muscle
and circulation of SOD1-G93A model of ALS, and used the
obtained results to conduct the first investigation of miRNA
alterations in the circulation of ALS patients. The most
outstanding result is that levels of miR-206, which is known to
Figure 1. miRNA alterations in the skeletal muscle of symp-
tomatic ALS mice. Venn diagram showing the significant (p,0.05)
changes observed in EDL (green, total 179 changes) and SOL (orange,
total 42 changes) muscles of SOD1-G93A mutants (+) compared with
wild type (2) littermates. Arrows pointing up and down indicate
upregulation and downregulation, respectively. An overlap with the
two muscle types was observed in 12 probe sets, only three of which
were changed in the same direction (brown square). Total 1412 Mus
musculus miRNA probe sets were analysed using Affymetrix GeneChip
miRNA 2.0 Arrays. Significantly affected non-miRNA species (n = 8), such
as fragments of tRNA, rRNA and the mitochondrial genome, are not
included in the data but are listed in Tables S1 and S2.
doi:10.1371/journal.pone.0089065.g001
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be involved in the maintenance of neuromuscular connectivity in
ALS mice [44], are elevated not only in the affected muscle of both
male and female SOD1-G93A mice but also in the blood plasma
of these animals and in serum samples from human ALS patients.
The number of miRNA alterations in the hybridization data
(Figures 1 and S1) is in agreement with fast-twitch muscles being
more affected in SOD1-G93A model than slow-twitch muscles
[26–29]. As postnatal skeletal muscles can adapt by switching fiber
type depending on motoneuron activity [45], preferential motor
unit loss and reinnervation of the fast fibers by surviving motor
units leads to a fast-to-slower fiber type transition in SOD1-G93A
mice [46]. EDL of mice consist mainly of type IIB and IIDB fibers,
whereas SOL is composed mainly of type I, IIA and IIAD fibers
[47]. Interestingly, a large number of miRNAs that in control
animals were enriched in the slow SOL muscle were here
upregulated in fast EDL muscle of SOD1-G93A (upward arrows
in Table S3). In contrast, many of those normally enriched in fast
muscle showed diminished expression in SOD1-G93A EDL
(downward arrows, Table S3). This could suggest that fiber type
transition described in SOD1-G93A fast-twitch muscle is reflected
by the corresponding fast-to-slow transition in the miRNA profile,
and that the regulated miRNA may have a role in the
determination of fiber type or associated metabolic switch.
However, it is equally possible that the mSOD1 associated
miRNA alterations are just reflecting the fiber type transition
without playing active part in the process. The latter is supported
by the observation that the two known miRNAs involved in fast-
to-slow fiber programs, miR-208b and miR-499 [48], were not
affected in SOD1-G93A model (although miR-208b was found to
be slow-twitch enriched in both mutant and control animals,
Tables S3 and S4).
Of those miRNAs ultimately selected for qPCR verification,
several were under detection limit in one or both muscles, and
some most upregulated miRNAs were absent in circulation. One
of the indications of the presented mouse work is that the
microarray data should be interpreted with caution, especially
when the signal intensities are low. Although microarrays are
useful in screening large number of potential miRNA candidates
and, therefore, creating lists of potentially altered miRNA for
further work, it may be misleading to publish these data without
confirmation using more accurate methods.
When all ages are combined, the only consistently altered
miRNA in the course of ALS pathology in SOD1-G93A mice was
miR-206. The increase in the levels of miR-206 was first
significant in the symptomatic stage, consistent with its upregula-
tion in denervated tibialis anterior (TA) muscle and in symptom-
atic TA muscle of a similar ALS model [44]. miR-206 expression
is controlled by myogenic regulatory transcription factors includ-
ing myogenin and MyoD that are also upregulated by denervation
[49–51]. Upregulation of miR-206 in male EDL and plasma was
close to significance at presymptomatic stage, which suggests that
the threshold of fast muscle denervation at which miR-206
expression is induced is crossed between postnatal days 60 and 90,
where also the myogenic factors involved in miR-206 transcription
are induced [23]. miR-206 and miR-133b are clustered, and their
co-expression as bicistronic transcript in myogenic conversion
in vitro and in denervation in vivo has been documented [44,50].
Here, however, miR-206 upregulation in SOD1-G93A mice was
not associated with miR-133b upregulation at any stage. Similar
results have been obtained in Duchenne muscular dystrophy
model (mdx) suggesting that in some conditions the two miRNAs
are under independent transcriptional control [52].
Elevated circulating miR-206 levels were detected in both sexes
of SOD1-G93A mice, although the level and age at which this
occurred differed according to the symptomatic onset (males are
affected earlier in this model). Furthermore, although miR-206
levels in male EDL muscle progressively increased towards the
terminal stage (Figure 2A), its circulating levels (Figure 2B) were
Table 1. Relative* miRNA alterations verified by qPCR in SOD1-G93A animals.
Tissue miRNA P60 p (P60) P90 p (P90) P120 p (P120)
EDL miR-206 1.7 (M) 0.1 7.7 (M)/7.7 (F) 0.0001/0.001 11.7 (M)/4.2 (F) 0.0001/0.03
miR-1 – – 0.5 (F) 0.1 0.4 (F) 0.05
miR-133a – – 0.6 (F) 0.004 – –
miR-133b – – – – 0.7 (F) 0.04
miR-106b – – 2.3 (M) 0.11 – –
Plasma miR-206 3.8 (M) 0.1 4.5 (M)/3.3 (F) 0.0004/0.09 0.6 (M)/4.2 (F) 0.04/0.02
miR-1 – – – – 0.2 (M) 0.001
miR-133a – – – – 0.3 (M)/2.6 (F) 0.005/0.1
miR-133b – – – – 0.3 (M) 0.01
miR-145 – – 1.7 (M) 0.12 0.5 (M) 0.04
miR-21 – – – – 0.5 (M) 0.05
miR-24 – – – – 0.5 (M) 0.03
miR-106b 2.3 (M) 0.1 – – – –
SOL miR-206 N/A N/A – – – –
miR-1 N/A N/A 0.7 (M) 0.1 0.5 (M)/0.6 (F) 0.002/0.06
miR-133a N/A N/A 0.8 (M) 0.01 – –
miR-133b N/A N/A 0.7 (M) 0.1 – –
miR-145 N/A N/A 0.7 (M)/0.6 (F) 0.02/0.1 0.7 (M)/0.6 (F) 0.08/0.01
Significant results (p,0.05) shown in bold, those close to significance (0.05,p.0.15) in normal font.
*Relative numbers .1 refer to upregulation, and those ,1 to downregulation. Abbreviations: M, males; F, females; p(PX), p-value at indicated postnatal day X.
doi:10.1371/journal.pone.0089065.t001
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decreased at the terminal stage where muscles are severely
atrophic. Therefore, although severe muscle atrophy could
dampen miR-206 expression directly, this is not supported at
least in males where the most severely damaged EDL shows the
highest miR-206 expression. However, the release or secretion of
miRNAs from the muscle tissue to the circulation, including that of
miR-206, may be a regulated process that requires uncompro-
mised muscle function which is lost at the terminal disease stage
(between P100 and P120). This conclusion may be supported by
the general finding that seven out of 11 tested miRNAs were
significantly downregulated in the circulation of terminal stage
males (Table 1). Discrepancies between miRNA expression
between the muscle tissue and serum have been also described
in mdx mice, where many myomirs are highly abundant in plasma
without alterations in the muscle [53–55]. However, it cannot be
excluded that other factors influencing miRNA stability in the
circulation may be affected.
Many miRNAs are expressed in a tissue-specific manner.
Myomirs are miRNAs whose expression is enriched in striated
and/or cardiac muscle, and are involved in myogenesis, develop-
mental muscle growth and cardiac function [56]. Increase in
circulating myomirs miR-1, miR-133a, miR-133b and miR-206
Figure 2. miR-206 is elevated in fast-twitch muscle and circulation of SOD1-G93A males. A) Relative miR-206 expression in male SOD1-
G93A muscles at various stages of the pathology (P10– P120). Wild type (set as 1) is shown as dark green, SOD1-G93A as light green. EDL is shown as
solid bars, SOL as hatched bars. B) Relative miR-206 expression in male SOD1-G93A plasma. Wild type (set as 1) is shown as dark blue, SOD1-G93A as
light blue. C) Relative miR-206 expression in SOD1-G93A plasma from symptomatic animals at postnatal day 100. The expression values are relative to
the age-matched controls obtained by 22DDCt method and the error bars are those obtained after 22DDCt conversion of standard deviation (see
materials and methods). (*)p = 0.1 (close to significance), *p,0.05 (significant), ***p,0.001(highly significant).
doi:10.1371/journal.pone.0089065.g002
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have been demonstrated in various models of striated muscle
pathologies [41,53,57] whereas they are frequently downregulated
in cancer [58]. Although miR-206 is the only myomir whose
expression was described to be striated muscle-specific, it has
subsequently been shown to be expressed also in brown fat [59], in
liver [60], in subset of helper T-cells [61], and in breast tissue
where its expression may be under hormonal control [62]. miR-
206 is also elevated in the nervous system in various pathological
conditions including Alzheimer’s disease and cerebral ischemia
[63,64], in schizophrenia [65], as well as in cytotoxic insult upon
exposure to environmental toxin [66]. This may indicate
pathological induction of miR-206 in the neuronal or associated
cells where it is not normally expressed. Alternatively, muscle-
derived circulating miRNAs may be actively transported to other
cell types via extracellular vesicles, where they may possibly act as
posttranscriptional regulators [40].
miR-206 is important for differentiation of myoblasts as it
downregulates of several inhibitors myogenesis [67]. On the other
hand, it seems to be dispensable for maintaining post-natal skeletal
muscle mass [68]. Deletion of miR-206 in vivo does not lead to
Figure 3. miR-206 is elevated in fast-twitch muscle and circulation of SOD1-G93A females. A) Relative miR-206 expression in female
SOD1-G93A muscles at various stages of the pathology (P60– P120). B) Relative miR-206 expression in female SOD1-G93A plasma. See text and
Figure 2 for details.
doi:10.1371/journal.pone.0089065.g003
Figure 4. miR-206 and miR-106b are elevated in the circulation of ALS patients. Relative expression of 11 miRNAs studied in definitive ALS
patients (n = 12) vs. healthy controls (n = 12). See text for details. *p,0.05 (significant), **p,0.01(very significant).
doi:10.1371/journal.pone.0089065.g004
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muscle atrophy or alterations in NMJ maturation. Instead, miR-
206 upregulation is required for formation of new NMJs after
nerve injury and contributes to the capability to maintain
neuromuscular connections in SOD1-G93A animals in vivo by
potentiating the function of muscle-derived factors on NMJ
regeneration [44]. Besides the protective role of miR-206 in
SOD1-G93A model, its other potential functions in ALS remain
unknown. Among the thousands of miR-206 target transcripts
predicted by various bioinformatics tools [69] more than 50 are
experimentally validated (Table 2). These include a large number
of factors involved in transcriptional regulation (transcription
factors and those involved in associated chromatin modifications),
cell cycle and signaling, secreted factors and receptors, as well as
proteins that function in synaptic or cell junctions. Because
miRNA target validation methodology relies largely on in vitro
assays these factors may or may not have a direct role in tissues
contributing to ALS pathogenesis. Although many forms of
posttranscriptional regulation are not obvious from RNA-level
studies, it is noticeable that transcripts for nine of the listed targets
(BDNF, CCND2, IGFBP5, NFAT5, NOTCH3, OTX2,
SH3BGRL3, TIMP3, and TPPP) are downregulated in muscle
biopsies from ALS patients ([70], EBI-EMBL Expression Atlas ID
E-GEOD-3307). For example, IGFBP5 is a positive regulator of
IGF1 (also target of miR-206, Table 2) signalling and both are
severely reduced in ALS muscle [71]. Very little is known about
the other miRNA implicated in ALS patient samples, miR-106b.
It is known to be expressed from a conserved cluster including
three miRNAs (mir-106b, mir-93 and miR-25) that are involved in
cancer [72] and adult neural stem cell proliferation and
differentiation [73]. Additionally, miR-106b has been implicated
in brown adipocyte differentiation [74] and in suppression of
autophagy in cultured myoblasts [75]. Whether miR-206 and
miR-106b have a functional role in human ALS pathogenesis
needs further experimental focus, preferably using methodology
that can reveal miRNA target genes and pathways directly in the
affected tissues.
Because of mostly sporadic nature, rapid progression and
clinical heterogeneity of ALS, an early detection by biomarkers
affected in ALS but not other conditions that mimic the disease
would certainly be welcome in the community. Neurophysiolog-
ical and imaging techniques may be used to help disease
monitoring and get insight on disease prospects [76]. Additionally,
higher concentrations of phosphorylated neurofilament heavy
subunit (pNF-H) and cystatin C seem to be associated with more
rapid functional decline and survival in ALS patients, and could
therefore serve as potential prognostic biomarkers for the disease
[76]. However, many of these have been mainly assessed in
cerebrospinal fluid, and those obtainable by blood or other
accessible body fluids (urine, saliva etc.) would be desirable. The
two miRNAs found to be elevated here, miR-206 and miR-106b,
may provide ideal biomarkers as they can be sampled from blood.
Without doubt, more samples from ALS patients need to be
analysed to draw definitive conclusions about miRNA changes,
and other possible miRNA changes are warrant screening to
increase the power of the test. As the miR-206 profile in ALS mice
is profoundly altered depending on the severity of pathological
stage, it will be necessary to characterize the miRNA changes in a
larger number of patients involving samples from possible,
probable and definite ALS patient groups, as well as separating
the groups with bulbar and limb onset as well as demographic
factors etc. Importantly, a comparative study of circulating
miRNAs between ALS patients and disorders that mimic ALS
need to be conducted. This is crucial especially for the diagnostic
purposes, as with rare diseases the number of false positives may
greatly exceed the number of affected cases if the specificity of a
biomarker is not close to 100%. Recent data on mdx model of
Duchenne muscular dystrophy suggest that serum levels of several
Myomirs can be used as biomarkers of muscle turnover [41]. In
this model, the elevated circulating levels of miR-1, miR-133a and
miR-206 show dose-responsive restoration to wild type levels in
response to exon-skipping therapy that restores dystrophin levels.
Therefore, it may be plausible that miR-206 (and miR-106b) can
be used in the future to screen potential candidate drugs or
treatments for ALS.
In conclusion, the increased circulating miR-206 and miR-106b
may serve as biomarkers for ALS in humans. Further studies are
warranted to investigate the diagnostic or prognostic value of these
miRNAs within different subtypes of ALS as well as within
suspected population including ALS-like conditions. Importantly,
it will be of interest to evaluate the applicability of these miRNAs
as indicators of therapeutic response in pre-clinical testing and in
clinical trials.
Materials and Methods
Ethics Statement
All experimental animal procedures were approved (Ref. PI31/
10) by the Ethics Committee of Universidad de Zaragoza and
followed the international and the institutional guidelines for the
use of laboratory animals. Existing human serum samples were
from ALS Unit of Instituto de Investigacio´n Biome´dica Hospital
12 de Octubre, Madrid, Spain. They were stored in frozen state
until the study and were analysed anonymously. The present study
has been approved by the ethics committee ‘‘Comite´ e´tico de
investigacio´n clı´nica – CEIC’’ del Instituto de Investigacio´n
Biome´dica del Hospital 12 de Octubre ‘‘i+120. We have obtained
written informed consent of every patient included in this study.
Animals and Housing
The transgenic mice B6SJL-Tg(SOD1-G93A)1Gur/J [8] ex-
pressing a high copy number of the G93A mutant form of human
SOD1 were obtained from the Jackson Laboratory (Bar Harbor,
ME, USA) and were housed under a 12 h light: 12 h dark cycle in
21–23uC with relative humidity of 55%. Food and water were
available ad libitum. Transgenic animals were maintained by
breeding hemizygous SOD1-G93A males with B6SJL wild type
females. The genotype was determined from a tail sample as
described (http://www.jax.org/). Hemizygous SOD1-G93A mice
and their non-transgenic littermates were used for all experiments.
At the terminal stage, SOD1-G93A mice that were unable to right
themselves within 20 seconds when placed on their side were
sacrificed for ethical reasons.
Tissue Extraction
The blood was extracted from CO2-euthanized animals, after
which a cervical dislocation was performed before the muscle
dissection. Briefly, 0.4 ml blood was extracted from the heart using
sterile K3-EDTA –treated syringe with 25 gauge needle. Blood
was slowly transferred to a microcentrifuge tube containing 10 ml
K3-EDTA and centrifuged at 13006g for 10 minutes at 4uC and
120 ml plasma was collected without interference with the lower
cell fraction. Plasma samples were frozen within 30 minutes of the
sacrifice and stored at 280uC. Extensor digitorum longus (EDL)
and soleus (SOL) muscles were dissected immediately after the
blood extraction and submerged each in 0.5 ml RNAlaterH (Life
Technologies, Cat# AM7021). The samples were stored at +4uC
for 24 hours and then transferred to 280uC.
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Table 2. Experimentally verified targets for miR-206.
Evidence
Process Gene symbol Gene product function Experimental cells LUC WB qPCR NB Refs
Transcription/
chromatin
ACTL6A Subunit of SWI/SNF complex HEK293, NIH10T1/2 N N [79]
CLOCK bHLH transcription factor indirect evidence [56,80]
ESR1 estrogen hormone receptor MCF-7, MDA-MB-231 N N N [62]
HDAC4 histone deacetylase COS1, miR-206-KO N N [44,68,81]
HIF1A* hypoxic transcriptional activator PASMC N N N [82]
HMGB3 high mobility group box protein HEK293 N N [83]
KLF4** transcription factor HMEC, RK3E, MCF10A N N [84,85]
MEOX2 homeobox transcription factor NIH3T3, DF1 N N [67]
MSC transcriptional repressor C2C12 N [86]
NCOA1 & NCOA3 nuclear receptor coactivators MCF-7 N N [87]
NFAT5 transcription factor NIH3T3, DF1 N N [67]
OTX2 homeobox transcription factor U343, SK-N-SH N N N [88]
PAX3 paired box transcription factor HEK293, C2C12, SMSC N N [89–92]
PAX7 paired box transcription factor SMSC, C2C12, N N N [52,93–95]
RARB retinoic acid receptor C2C12, NIH3T3, DF1 N N [67]
SMARCB1 SWI/SNF transcriptional co-activator C2C12, NIH3T3, DF1 N N [67]
SMARCD2 SWI/SNF transcriptional co-factor C2C12, NIH3T3, DF1 N N [67]
SNAI2 transcriptional repressor SMSC, COS7 N N [96]
Cell signaling HHIP hedgehog signalling inhibitor C2C12 N [86]
MAP4K3 MAP protein kinase C2C12, NIH3T3, DF1 N N [67]
NRP1 Cell migration signalling AML12 N [97]
PRICKLE1 Wnt/beta-catenin signaling zebrafish embryo N [98]
PTPLAD1 Rac1 signaling C2C12 N N [86]
Cell cycle CCND1 & CCND2 G1/S-specific cyclins RMS, GC, C2C12, HeLa N N N N [92,99,100]
CDC42 small GTPase of the Rho-subfamily MDA-MB-231 N [101]
ID1, ID2 & ID3 dominant negative HLH proteins C2C12 N [86]
POLA1 DNA replication C2C12 N N [86]
Secreted
factor
BDNF growth factor C2C12, HEK293T, N2a N N N N [86,102–104]
FSTL1 glycoprotein of the follistatin family MEF N N [105]
IGF1 growth factor HEK293 N [106]
IGFBP5 IGF binding protein (stimulatory) miR-206-KO SMSC N N N [95]
TAC1 peptide hormone/neurotransmitter MSC, MSC-NC N N [107]
VEGFA growth factor LSCC N [108]
Membrane
receptor
FZD7 Wnt signaling receptor C2C12, NIH3T3, DF1 N N [67]
MET hepatocyte growth factor receptor RMS, SMSC N N [109,110]
NGFR nerve growth factor receptor C2C12 N N [103]
NOTCH3 Notch signalling receptor HeLa, MEFs, SMSC N N N [95,111,112]
Synapse/
junction
GJA1 gap junction protein C2C12, mouse N N N [67,86,113]
IGSF5 tight junction adhesion molecule C2C12 N [86]
UTRN NMJ and cytoskeleton component MEF N N N [105]
Others CLCN3 endosome/synaptic vesicle antiporter C2C12, NIH3T3, DF1 N N [67]
GPD2 mitochondrial dehydrogenase AML12 N [97]
MMD monocyte to macrophage
differentiation
C2C12 N N N [86]
MUP1 glucose and lipid metabolism AML12 N [97]
SH3BGRL3 TNF inhibitory protein DF1 N [67]
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RNA Extraction
For microarrays, muscle tissues stored frozen in RNAlater were
pulverized in a mortar under liquid nitrogen. The total RNA was
extracted using mirVana miRNA Isolation Kit (Life Technologies,
Cat# AM1560) according to kit instructions. Each RNA sample
was eluted in 100 ml of RNase free water. The quality and quantity
of each extraction was confirmed by Bioanalyzer H (Agilent
Technologies) and Nanodrop ND-1000 spectrophotometer
(Thermo Scientific). The mean RNA integrity (RIN) number of
the samples was 9.1 (range 8.6–9.5). For qPCR, the individual
muscles stored frozen in RNAlater were homogenized in
Cellcrusher cryogenic tissue pulverizer (Cellcrusher, Cork, Ireland)
submerged in liquid nitrogen. The frozen muscle powder was
transferred to a microcentrifuge tube containing 0.5 ml QIAzol
lysis reagent (Qiagen, Cat# 79306), then further processed by
passing 10 times through a 23 gauge needle and centrifuged
120006g for 1 minute. Without disturbing the insolubilized pellet,
0.45 ml Trizol/muscle lysate was transferred into a new tube and
RNA was purified using Direct-zol RNA miniprep (Zymo
Research, Cat# R2052) following manufacturer’s instructions.
The samples were eluted in 50 ml RNase free water and stored at
280uC for further analysis. Plasma samples (each 120 ml) were
thawn on ice and re-centrifuged at 13006g for 5 minutes at 4uC.
Total plasma RNA (including miRNA) from exactly 100 ml of
plasma was extracted with Norgen Total RNA Purification kit
(Norgen Biotek Corporation, Cat# 17200) with minor modifica-
tions. Briefly, after inactivation of RNases with lysis solution,
carrier RNA (0.56 mg MS2 RNA, Roche, cat# 10165948001) and
spike-in miRNA (25 fmol synthetic cel-miR-39, Qiagen, Cat#
MSY0000010) was added for increased consistency of the RNA
isolation and for normalization, respectively. The plasma lysate
was passed through provided spin columns and washed 3 times
with absolute ethanol. RNA was eluted in 50 ml elution solution by
successive 2-minute centrifugations at 2006g and 14 0006g and
then immediately stored at 280uC. The RNA from human serum
samples were prepared as above, except starting from 200 ml
serum.
Microarrays
The microarray hybridization of microRNAs was performed by
Progenika Biopharma, Spain, using GeneChip H miRNA 2.0 chips
(AffymetrixH). These contain total 1412 mouse probesets (722
mature miRNA and 690 pre-miRNA species) that cover those
miRNAs included in miRBase v15 (ftp://mirbase.org/pub/
mirbase/15/). Left EDL and left SOL muscle from three
SOD1-G93A males and three age matched male littermates (total
12 samples) were analysed at the symptomatic age of 90 days.
From each sample, 1 mg of total RNA was used as a starting
material. Sample processing and hybridization, development,
scanning of the chips and analysis of the results was carried out
following the protocols and equipment recommended by Affyme-
trix Inc. The software used for processing chips and the results was
the Affymetrix GeneChip Command Console Software v3.0
(SCFA 3.0, Affymetrix H) and miRNA QCTool Software
(Affymetrix H). The software used for statistical analysis of the
results was PartekH Genomics SuiteTM and dChip (www.dchip.
org) [77]. Briefly, the probe intensity values were background
corrected, quantile-normalized and the probeset-level expression
signals were summarized with the robust multi-array average
(RMA) method. The significant differences (p-value .0.05, tables
S1–S4) in each muscle/genotype comparison were first deter-
mined by t-test. Because individual p-values for each probeset are
not the best measure of significance in the context of testing large
number of miRNAs, we then calculated the confidence of
microarray results using the false discovery rate (FDR). This
approach controls the number of false discoveries in ‘‘significantly
altered’’ probesets and determines adjusted p-values (FDR q-
values, tables S1–S4) for each test. Only two probesets were found
significant (q-value ,0.05) after FDR. Therefore, the miRNAs for
individual assays were selected weighing significance and the
expression fold-change, as well as other criteria explained in
‘‘Results’’. The microarray data in its completion will be available
for public access in NCBI Gene Expression Omnibus (GEO,
www.ncbi.nlm.nih.gov/geo).cDNA synthesis.
From each muscle RNA sample, 30 ng was used as a template
for RT with TaqManH MicroRNA Reverse Transcription Kit
(Life Technologies, Cat #4366596). For plasma samples, where
RNA quantification was not feasible, 5.35 ml spiked-in plasma
RNA was directly used as a template. The standard TaqManH
MicroRNA Assays protocol calls for an individual RT reaction for
each target miRNA. To facilitate the miR-cDNA synthesis,
multiplexed RT step was used that included pools of individual
RT primers. RT primer pools were prepared as instructed by the
manufacturer (Life Technologies). Multiplex ‘23X-pool’ was
prepared by mixing 23 individual TaqMan miRNA assays of
interest (those listed in Figure S4, excluding miR-206), as well as
those of snoRNA-202 or cel-miR-39 for normalization of muscle
and plasma samples, respectively (see below). For miR-206, RT
Table 2. Cont.
Evidence
Process Gene symbol Gene product function Experimental cells LUC WB qPCR NB Refs
TIMP3 metalloproteinase inhibitor CF N N N [114]
TPPP microtubule network organizer CG4, HeLa N [115]
FN1 cell adhesion, migration H441 N N N [116]
*Hif1a upregulation in protein level, downregulation in mRNA level and LUC assay, **miR-206 can stimulate (normal cells) or repress (cancer cells) KLF4 translation.
Abbreviations: LUC, luciferase assay; WB, western blot; qPCR, quantitative PCR; NB, northern blot; HEK293, human embryonic kidney cells; NIH10T1/2, fibroblasts; MCF-7,
breast cancer cell line; MDA-MB-231, human adenocarcinoma cells; miR-206-KO,miR-206 knockout mouse; PASMC, pulmonary artery smooth muscle cells; HMEC, human
mammary epithelial cells; RK3E, rat kidney cells; MCF10A, mammary epithelial cells; NIH3T3, mouse embryonic fibroblast cells; DF1, chicken embryonic fibroblasts; U343,
human glioma cells; SK-N-SH, human neuroblastoma cells; C2C12, immortalized mouse skeletal myoblasts; SMSC, mouse skeletal muscle satellite cells; RuGli, rat glioma
cells; COS7, African green monkey kidney cells; AML12, mouse hepatocytes; RMS, rhabdomyosarcoma cells; GC, human gastric cancer cells; HEK293T, human embryonic
kidney cells with SV40 Large T-antigen; N2a, mouse neuroblastoma cells; SH-SY5Y, human neuroblastoma cells; MEF, mouse embryonic fibroblasts; MSC, human
mesenchymal stem cells; MSC-NC, human mesenchymal stem cell-derived neural cells; HeLa, human epithelial cells from cervical carcinoma; CF, cardiac fibroblasts; CG,
rat oligodendrocyte progenitor cells; H441, human lung adenocarcinoma epithelial cells.
doi:10.1371/journal.pone.0089065.t002
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pool ‘206-pool’ was prepared separately with snoRNA-202 or cel-
miR-39 as the interference of miR-206 with highly homologous
miR-1 did not allow these RT primers to be included in the pool.
Significant results derived from the pooled RT reactions were later
confirmed using individual RT reactions.
Quantitative PCR
Individual TaqManH miRNA assays (Life Technologies) were
used to quantify the muscle and plasma-expressed miRNAs. The
muscle samples were normalized with snoRNA202. As no
endogenous circulating miRNA with proven suitability for qPCR
normalization currently exist, equal amount of plasma was used as
starting material. To allow normalization for potential variability
in the RNA extraction step the plasma samples were spiked in with
25fmol synthetic C. elegans miR-39 (cel-miR-39) which does not
have orthologs in mammalian species. Each condition (genotype,
sex, age) contained minimum 6 biological replicates (animals).
qPCR from each sample was run in three technical replicates. For
sample normalization, mean cycle threshold (Ct) values of
snoRNA202 (for muscle) or cel-miR-39 for (spiked-in plasma/
serum) were subtracted from the mean Ct values or the miRNA
under study (DCt). Within same sex and age, the mean of control
animal DCt values were then subtracted from the mean of mutant
animal DCt values (DDCt). The exponential process was converted
to the linear relative comparison by 22DDCt conversion. The
control group in each comparison was used as a calibrator
(DDCt = 0, 22DDCt = 1). The positive and negative error
values (error bars) were also determined using 22DDCt method
[78]. Statistical analysis was performed by means of Student’s t-
test, where values were considered statistically significant at P,
0.05.
Supporting Information
Figure S1 Heatmap of hierarchical cluster analysis of
microarray samples. Summarized intensity values from the
differentially expressed miRNAs in EDL and SOL muscles of wild
type (2) and SOD1-G93A (+) animals are shown. Data includes
187 and 42 probesets from tables S1 and S2 respectively. The log2
intensity values are shown in the bar scale. Hierarchical
dendrograms are shown above the heatmaps and the numbers
indicated (12SEXXX) denote the sample IDs for EDL2
(12SE849-51), EDL+ (12SE852-54), SOL- (12SE855-57) and
EDL+ (12SE858-60).
(TIF)
Figure S2 Highly upregulated probesets are mostly
mature miRNA. The ten most overexpressed mature miRNAs
are more upregulated than those corresponding to miRNA* or
pre-miRNA species. Average relative expression values (EDL+ vs
EDL2) of ten most upregulated (red) and ten most down regulated
(green) probesets are shown for mature miRNAs (miRNA),
passenger strand (miRNA*) and pre-miRNAs. The error bars
are standard error of mean (SEM). ***p,0,001, **,0,01.
(TIF)
Figure S3 The probesets affected more than 2-fold in
SOD1-G93A EDL muscle. Average relative expression values
(EDL+ vs EDL2) of probesets upregulated or downregulated at
least 2-fold are shown. Blue bars represent mature miRNAs, red
bars miRNA* species, and green bars pre-miRNAs. The identities
of the specific Affymetrix probesets are indicated on the X-axis.
See text for details.
(TIF)
Figure S4 Determining the detection limits for qPCR. A)
Cutoff values (Ct) for 24 miRNAs were determined from EDL
(blue bars), SOL (red) and plasma (green) samples. Cutoff for
significant expression was set to 32 (dashed red line), at least in
plasma and one of the muscles (EDL or SOL). B) Numerical data
for graph shown in A. The assays selected for the final qPCR
verification are indicated in column ‘‘selected’’.
(TIF)
Figure S5 Data for Figure 4 genders separated. A)
Relative serum levels of 11 miRNAs studied in definitive ALS
male patients (n = 6) vs. healthy control males (n = 6). B) Relative
serum levels of 11 miRNAs studied in definitive ALS female
patients (n = 6) vs. healthy control females (n = 6). See text for
details. (*)p,0.01(close to significance), *p,0.05 (significant).
(TIF)
Table S1 Microarray changes in SOD1-G93A EDL
muscle compared with wild type EDL. All significant
changes without multiple corrections are listed. Positive fold
change (FC) indicates higher expression in the SOD1-G93A
mutants, and negative FC lower higher expression in the wild type
animals. Probeset ID refers to the Affymetrix probeset identifier.
(PDF)
Table S2 Microarray changes in SOD1-G93A SOL
muscle compared with wild type SOL. All significant
changes without multiple corrections are listed. Positive fold
change (FC) indicates higher expression in the SOD1-G93A
mutants, and negative FC lower higher expression in the wild type
animals. Probeset ID refers to the Affymetrix probeset identifier.
(PDF)
Table S3 Preferential expression of microarray probe-
sets in wild type EDL vs wild type SOL. All significant
changes without multiple corrections are listed. Positive fold
change (FC) indicates preferential (higher) expression in the wild
type EDL, and negative FC lower preferential expression in the
wild type SOL. Probeset ID refers to the Affymetrix probeset
identifier.
(PDF)
Table S4 Preferential expression of microarray probe-
sets in SOD1-G93A EDL vs SOD1-G93A SOL. All significant
changes without multiple corrections are listed. Positive fold
change (FC) indicates preferential (higher) expression in the
SOD1-G93A EDL, and negative FC lower preferential expression
in the SOD1-G93A SOL. Probeset ID refers to the Affymetrix
probeset identifier.
(PDF)
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